Jill Taylor

Chicago-The expense of latanoprost (Xalatan, Pfizer Ophthalmics) treatment may be driven down with the use of a relatively new device that assists patients in proper administration of the eye drops, according to a research team led by Sriram Sonty, MD, FACS, clinical associate professor, University of Illinois, Chicago Eye Center.

Charleston, SC-By implementing a different treatment regimen in each eye of patients with glaucoma, Alfred M. Solish, MD, found that not only does bimatoprost (Lumigan, Allergan) appear more effective than travoprost (Travatan, Alcon Laboratories) for reducing IOP, but also when given a choice of treatment, patients tend to prefer bimatoprost for that reason. Dr. Solish presented the results of that analysis in a poster at the American Glaucoma Society annual meeting.

Fort Lauderdale, FL-Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P, Allergan) is an effective adjunctive therapy in patients with glaucoma using latanoprost (Xalatan, Pfizer Ophthalmics) who require additional IOP lowering, according to research reported at the Association for Research in Vision and Ophthalmology annual meeting.